ArticleCancer2018

A study of axitinib, a VEGF receptor tyrosine kinase inhibitor, in children and adolescents with recurrent or refractory solid tumors: A Children's Oncology Group phase 1 and pilot consortium trial (ADVL1315).

James I Geller et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.